- 7 hrs ago What Are Leptin And Ghrelin And How Do They Affect The Body Weight?
- 7 hrs ago Vikrant Rona Actress Jacqueline Fernandez Goes Retro In Co-ord Set! PICS
- 8 hrs ago What Is Short Bowel Syndrome? Causes, Symptoms, Complications And Treatments
- 12 hrs ago South Africa In New Surge Of COVID-19 From Versions Of Omicron
- Finance Stocks To Buy: These 3 Stocks Can Gain Upto 39% In 1 Year, Stable Volume Growth Reported
- Sports IPL 2022 PBKS vs DC, Highlights: Delhi Capitals beat Punjab Kings by 17 runs, inch closer to play-offs berth
- News Elisabeth Borne appointed France's new PM, second woman to hold post
- Movies Shailesh Lodha Quits Taarak Mehta Ka Ooltah Chashmah; Actor Is No Longer Shooting For The Show - Reports
- Education TANCET 2022 Result: Anna University To Announce Results In June Second Week. Check Dates And Other Details
- Automobiles CNG Price Hiked Again: Rs 2 Increased Per Kg
- Technology Vivo Y01 Launched As Brand’s Latest Entry-Level Phone: Features & Price
- Travel 10 Wonderful Destinations In Madhya Pradesh You Must Visit
Two babies have received the first-ever gene therapy for Tay-Sachs disease after over 14 years of development.
Tay-Sachs is a severe neurological disease caused by a deficiency in an enzyme called HexA. This enzyme breaks down a fatlike substance that normally exists in very small, harmless amounts in the brain. Without HexA, however, this fatlike substance can accumulate to toxic levels that damage and kill neurons.
One of the symptoms of this disease was first described in 1883 by British ophthalmologist Warren Tay, who saw a cherry-red spot on the back of the eye of affected infants. In 1887, American neurologist Bernard Sachs described the profound neurological symptoms of Tay-Sachs in a seminal paper:
"... Nothing abnormal was noticed until the age of two to three months, when the parents observed that the child was much more listless than children of that age. ... The child would ordinarily lay upon its back, and was never able to change its position ... it never attempted any voluntary movement ... the child grew steadily weaker, it ceased to take its food properly, its bronchial troubles increased, and finally, pneumonia set in, it died August, 1886."
This dismal description of Tay-Sachs remains current, and those with the disease usually die by age 5. Some people develop Tay-Sachs later in life, with symptoms starting in their teens that get progressively worse over many decades.
Unfortunately, there is still no treatment for Tay-Sachs. Aggressive medical treatment can extend survival but doesn't improve neurological function. The only effective way to treat Tay-Sachs is to restore the HexA enzyme in the brain. This is difficult, however, because the blood-brain barrier prevents most molecules from passing into the brain.
I am a member of a team of researchers from UMass Chan Medical School and Auburn University who developed a gene therapy that may help get around this barrier.
Our treatment uses two harmless viral vectors to deliver DNA instructions to brain cells that teach them how to produce the missing enzyme. Similar techniques have been used to treat a number of related diseases and other conditions.
In the case of Tay-Sachs, these DNA instructions enter the nucleus of these cells and stay there, allowing for the long-term production of HexA. Based on our previous studies successfully testing our gene therapy on different animal species, we believe that delivering the treatment to a central part of the brain allows the enzyme to travel along its connections to other regions and to be distributed throughout the entire brain.
The first child who received our gene therapy treatment was age 2 ½, with late-stage disease symptoms. Three months after treatment, they had better muscle control and could focus their eyes. Now at age 5, the child is in stable health and is seizure-free, which usually isn't possible for patients at this age. A second child treated at age 7 months had improved brain development by the three-month follow-up and remains seizure-free at a little over age 2.
More testing is needed to confirm whether our treatment can fully stop disease progression. Given that this was the first time our treatment was given to humans, we used a conservative dose below the maximum therapeutic effects we saw in our animal studies. My colleagues and I are currently conducting a follow-up clinical trial to test the safety and efficacy of increasing doses in a larger number of patients.
The increasing cost of manufacturing these treatments makes it extremely difficult, if not impossible, to develop and test gene therapy for many ultrarare diseases where the number of patients worldwide is very small and profitability low.
We were able to deliver these treatments to the children in our ongoing clinical trials thanks only to funding from a generous family whose own child is a participant. This grassroots approach is a common theme in ultrarare disease research - development and testing are often supported by parents, foundations and federal grants.
Our Translational Institute for Molecular Therapeutics programme at UMass Chan Medical School focuses on developing more viral vector gene therapies for an ever-expanding number of ultrarare diseases in collaboration with families and foundations. We believe every patient afflicted with any of the approximately 7,000 rare diseases worldwide deserves a chance at a normal life.
- wellnessCancer Patients Cured 10 Years After Gene Therapy Aka CAR-T Cell Therapy, Reveal Doctors
- disorders cureGene Therapy Helps Prevent Asthma - Study
- wellnessCovid-19 Severity Among Elderly May Be Due To Genetic Reasons, Study Reveals
- wellnessGenetic Link Between Routine Blood Test Results And Mental Health Disorders: Study
- healthScientists Develop New AI Model To Discover Genetic Risk Factors For Motor Neurone Disease
- diabetesKnow About Genetics Of Type 1 And Type 2 Diabetes And How To Prevent If It Runs In The Family
- disorders cureAchondroplasia: Causes, Symptoms, Diagnosis And Treatment
- disorders cureHuntington’s Disease: Causes, Symptoms, Diagnosis And Treatment
- disorders cureGene Editing: Everything You Need To Know
- wellnessRare Gene Variant Behind Schizophrenia Identified
- newsScientists Discover Gene That Causes Vision Loss; Foods That Are Good For Your Sight
- wellnessHeart Disease Preventing Gene Identified In Greeks